Abstract
N6-methyladenosine (m6A) has been identified as the most abundant internal modification of messenger RNA in eukaryotes1. m6A modification is involved in cell fate determination in yeast2,3 and embryo development in plants4,5. Its mammalian function remains unknown but thousands of mammalian mRNAs and long non-coding RNAs (lncRNAs) show m6A modification6,7 and m6A demethylases are required for mammalian energy homeostasis and fertility8,9. We identify two proteins, the putative m6A MTase, methyltransferase-like 3 (Mettl3; ref. 10), and a related but uncharacterized protein Mettl14, that function synergistically to control m6A formation in mammalian cells. Knockdown of Mettl3 and Mettl14 in mouse embryonic stem cells (mESCs) led to similar phenotypes, characterized by lack of m6A RNA methylation and lost self-renewal capability. A large number of transcripts, including many encoding developmental regulators, exhibit m6A methylation inversely correlated with mRNA stability and gene expression. The human antigen R (HuR) and microRNA pathways were linked to these effects. This gene regulatory mechanism operating in mESCs through m6A methylation is required to keep mESCs at their ground state and may be relevant to thousands of mRNAs and lncRNAs in various cell types.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
RBFOX2 recognizes N6-methyladenosine to suppress transcription and block myeloid leukaemia differentiation
Nature Cell Biology Open Access 28 August 2023
-
Exon-intron boundary inhibits m6A deposition, enabling m6A distribution hallmark, longer mRNA half-life and flexible protein coding
Nature Communications Open Access 13 July 2023
-
Epigenetic modification of m6A regulator proteins in cancer
Molecular Cancer Open Access 30 June 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout





Accession codes
References
Jia, G., Fu, Y. & He, C. Reversible RNA adenosine methylation in biological regulation. Trends Genet. 29, 108–115 (2013).
Clancy, M. J., Shambaugh, M. E., Timpte, C. S. & Bokar, J. A. Induction of sporulation in Saccharomyces cerevisiae leads to the formation of N6-methyladenosine in mRNA: a potential mechanism for the activity of the IME4 gene. Nucleic Acids Res. 30, 4509–4518 (2002).
Agarwala, S. D., Blitzblau, H. G., Hochwagen, A. & Fink, G. R. RNA methylation by the MIS complex regulates a cell fate decision in yeast. PLoS Genet. 8, e1002732 (2012).
Zhong, S. et al. MTA is an Arabidopsis messenger RNA adenosine methylase and interacts with a homolog of a sex-specific splicing factor. Plant Cell 20, 1278–1288 (2008).
Bodi, Z. et al. Adenosine methylation in Arabidopsis mRNA is associated with the 3’ end and reduced levels cause developmental defects. Front. Plant Sci. 3, 1–10 (2012).
Meyer, K. D. et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell 149, 1635–1646 (2012).
Dominissini, D. et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485, 201–206 (2012).
Zheng, G. et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol. Cell 49, 18–29 (2013).
Jia, G. et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 7, 885–887 (2011).
Bokar, J. A., Shambaugh, M. E., Polayes, D., Matera, A. G. & Rottman, F. M. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA 3, 1233–1247 (1997).
Bujnicki, J. M., Feder, M., Radlinska, M. & Blumenthal, R. M. Structure prediction and phylogenetic analysis of a functionally diverse family of proteins homologous to the MT-A70 subunit of the human mRNA:m(6)A methyltransferase. J. Mol. Evol. 55, 431–444 (2002).
Petrossian, T. C. & Clarke, S. G. Uncovering the human methyltransferasome. Mol. Cell. Proteom. 10, M110.000976-1-12 (2011).
Ku, M. et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet. 4, e1000242 (2008).
van den Berg, D. L. et al. An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell 6, 369–381 (2010).
Srikantan, S., Tominaga, K. & Gorospe, M. Functional interplay between RNA-binding protein HuR and microRNAs. Curr. Protein Peptide Sci. 13, 372–379 (2012).
Kundu, P., Fabian, M. R., Sonenberg, N., Bhattacharyya, S. N. & Filipowicz, W. HuR protein attenuates miRNA-mediated repression by promoting miRISC dissociation from the target RNA. Nucleic Acids Res. 40, 5088–5100 (2012).
Kishore, S. et al. A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nat. Methods 8, 559–564 (2011).
Lebedeva, S. et al. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. Mol. Cell 43, 340–352 (2011).
Le, M. T. et al. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet. 7, e1002242 (2011).
Lu, L., Katsaros, D., de la Longrais, I. A., Sochirca, O. & Yu, H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 67, 10117–10122 (2007).
Leung, A. K. et al. Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with and without mature microRNAs. Nat. Struct. Mol. Biol. 18, 237–244 (2011).
Zhao, J., Sun, B. K., Erwin, J. A., Song, J. J. & Lee, J. T. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 322, 750–756 (2008).
Harper, J. E., Miceli, S. M., Roberts, R. J. & Manley, J. L. Sequence specificity of the human mRNA N6-adenosine methylase in vitro. Nucleic Acids Res. 18, 5735–5741 (1990).
Zhao, J. et al. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol. Cell 40, 939–953 (2010).
Wang, Y. et al. Reprogramming of mouse and human somatic cells by high-performance engineered factors. EMBO Rep. 12, 373–378 (2011).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011).
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).
Li, H. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
Robinson, J. T. et al. Integrative genomics viewer. Nature Publishing Group 29, 24–26 (2011).
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Gen. Biol. 9, R137 (2008).
Durinck, S., Spellman, P. & Birney, E. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat. Protocol. 4, 1184–1191 (2009).
Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protocol. 4, 44–57 (2009).
Smyth, G. in Bioinformatics and Computational Biology Solutions Using R and Bioconductor (eds Gentle- man, R., Carey, V., Dudoit, S., Irizarry, R. & Huber, W.) 397–420 (Springer, 2005).
Mukherjee, N. et al. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol. Cell 43, 327–339 (2011).
Acknowledgements
We thank M. Wilkinson and all members of his laboratory for many valuable discussions; the Mass Spectrometry, Metabolomics, and Proteomics Facility at the University of Illinois at Chicago for measuring m6A/A ratios; S. S. Govindarajan from the Analytical Genomics core facility at the Sanford Burnham Medical Institute (Lake Nona) for performing the microarray analysis; and P. Ordoukhanian and S. R. Head from the Scripps Research Institute for high-throughput sequencing analysis. This work is supported by a CIRM Training Grant TG2-01162 (Y.W.), an AACR-Aflac, Career Development Award for Pediatric Cancer Research 12-20-10-ZHAO (J.C.Z.), the Ontario Research Fund - Global Leader (Round 2) and Natural Sciences and Engineering Research Council (NSERC; Z.Z.), and an NSERC Canada Graduate Scholarship and Ontario Graduate Scholarship (Y.L.). M.D.P. is an American Cancer Society Research Scholar (RSG-11-224-01-DMC). Z.Z. would like to dedicate this paper to the memory of S.Z.
Author information
Authors and Affiliations
Contributions
Y.W. generated Mettl3 and Mettl14 KD mESC lines, and using these lines, designed, performed and analysed most experiments, except meRIP, RIPs and EMSAs. meRIP, RIPs and EMSAs were performed by Y.W. and J.C.Z. Y.L. performed all bioinformatics analysis under the supervision of Z.Z. J.I.T. and M.D.P. purified luciferase, Mettl3 and/or Mettl14 proteins from baculovirus-infected Sf9 insect cells. J.C.Z. formulated, analysed and directed the study and wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Mettl3 and Mettl14 are required for m6A formation in vitro and in vivo.
A. Schematic drawing showing predicted MTase domains of mouse Mettl3 (Accession: NP_062695.2) and Mettl14 (Accession: NP_964000.2) proteins. Numbers represent amino acid numbers. B. RT-qPCR (left) and western blot (right) showing Mettl3 (left panel) and Mettl14 (right panel) expression in mESC clones stably expressing shRNAs targeting each. GapDH serves as a loading control in the western blot. Scr: scramble; shM3, shRNA against Mettl3; shM14, shRNA against Mettl14. The original gel is shown in Supplementary Fig. 5. C. Ethidium bromide staining (left panel) and m6A immunoblot (right panel) of DNA-free, rRNA-free Poly(A)+ RNA from Mettl3 kd, Mettl14 kd, and control cells. D. Measurement of percentage of m6A/A ratio by MS. E. Flag, Mettl3 or Mettl14 western immunoblots of proteins purified from lysates of HEK293 cells overexpressing flag-tagged Mettl3, Mettl14, or luciferase using M2 beads. Luc, luciferase; M3, Mettl3; M14, Mettl14. The original gel is shown in Supplementary Fig. 5. F. CPM counts of RNA probes extracted after an in vitro methylation assay. G. CPM counts of excised m6A spots from digested RNA probes used in the methylation assay. Error bars from panels B and F-G represent means ± SEM from 3 separate experiments, expect M3 in panel G where n = 7. One-tailed Student’s t-test, *P<0.05,**P<0.01,***P<0.001,****P<0.0001 vs. scramble control. Scr: scramble control.
Supplementary Figure 2 Mettl3 and Mettl14 interact and regulate each other’s stability.
A. meRIP-seq analysis of a Sox17 transcript showing loss of m6A methylation in both Mettl3 kd and Mettl14 kd cells. Yellow highlighting, peak location. Scr: scramble; shM3, shRNA against Mettl3; shM14, shRNA against Mettl14. B. Venn diagram showing overlap of Mettl3 and Mettl14 targets. C. Mettl3 or Mettl14 western immunoblots of endogenous proteins co-IP’d using antibodies against Mettl3 or Mettl14, or IgG in mESC lysates. M3, Mettl3; M14, Mettl14. The original gel is shown in Supplementary Fig. 5. D. Western blot analysis of Mettl3 and Mettl14 protein levels in Mettl3 kd and Mettl14 kd mESCs, respectively. The original gel is shown in Supplementary Fig. 5. E. RT-qPCR analysis of Mettl3 and Mettl14 RNA levels in Mettl3 kd and Mettl14 kd mESCs, respectively. F. GO analysis of 4395 shared Mettl3 and Mettl14 targets. Error bars from panel E represent means ± SEM from 3 separate experiments. One-tailed Student’s t-test, **P<0.01,***P<0.001 vs. scramble control. Scr: scramble.
Supplementary Figure 3 Mettl3 or Mettl14 knockdown mESCs lose self-renewal capability.
A. Phase contrast microscopy showing colony morphology of kd versus control mESC cells. Scr: scramble; shM3, shRNA against Mettl3; shM14, shRNA against Mettl14. B. Growth curve assessing cell proliferation kinetics of kd versus control cells. P values are generated by two-way ANOVA. C. Quantification of AP-positive colonies. D. Heat map analysis based on microarray comparison of gene expression in kd and control cells. E. RT-qPCR analysis of pluripotency (left) and differentiation (right) genes in kd versus control cells. F. GSEA analysis on enrichment of developmental regulators (left) and pluripotency-related genes (right) in Mettl3 kd versus control cells. A False Discovery Rate (FDR) of <0.178 was calculated for bivalent genes and FDR<0 for pluripotency-related genes. Note that FDR<0.25 is statistically significant for GSEA analysis: www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html. Scale bars, 100 μm. Error bars from panels B-C and E represent mean± SEM from 3 separate experiments. One-tailed Student’s t-test, *P<0.05,**P<0.01,***P<0.001,****P<0.0001 vs. scramble control. Scr: scramble.
Supplementary Figure 4 m6A modification regulates mRNA stability.
A. Enrichment of up- or down-regulated Mettl3 and Mettl14 targets in kd versus control cells. Arrows indicate up- or down regulation of gene expression. Scr: scramble; shM3, shRNA against Mettl3; shM14, shRNA against Mettl14. B. Comparison of cumulative transcript abundance in cells treated with Actinomycin D for 0, 4, and or 8 hrs by microarray analysis. RNAs from 0 hr serves as base-line. KS test, p<2.2e−16 comparing the changes in relative RNA levels from 4 to 8 hrs between Mettl targets and non-targets in both Mettl3 kd and Mettl14 kd cells. C. Enrichment of bivalent and pluripotency (Oct4 PPI) genes in shared Mettl3 and Mettl14 targets. D. meRIP-qPCR of specific bivalent and pluripotency genes (grey area). E. Enrichment of Mettl3 and Mettl14 targets showing increased RNA stability in kd cells among bivalent and pluripotency genes. F. Measurement of a percentage of m6A/A ratio by MS in undifferentiated (day 0), day6, and day 12 differentiated mESCs. G. RT-qPCR of Mettl3, Mettl14, and Rex1 expression in undifferentiated and differentiated mESCs. H. meRIP-qPCR of specific bivalent (gray area) and pluripotency genes in mESCs during differentiation. Error bars from panels D and G-H represent means ± SEM from 3 separate experiments. One-tailed Student’s t-test, *P<0.05,**P<0.01,***P<0.001,****P<0.0001 vs. scramble control. Scr: scramble.
Supplementary Figure 5 The HuR-microRNA pathway functions in m6A methylation-mediated RNA stability.
A. Enrichment of genes showing increased RNA stability following Mettl3 or Mettl14 kd among all shared Mettl3 and Mettl14 targets and among targets with and without canonical HuR binding sites in their 3’-UTR regions. M3, Mettl3; M14, Mettl14. B. Left panel, denaturing PolyAcrylamide Gel Electrophoresis (PAGE) showing the size of fragmented, DNAse-treated, rRNA-free mRNAs extracted from scramble and kd cells; mid-panel, non-denaturing PAGE showing differential binding of HuR to RNAs probes from left panel. Scr: scramble control, shM14, shRNA against Mettl14, shM3, shRNA against Mettl3. NP: no protein added. Right panel, non-denaturing PAGE showing differential binding of HuR to RNA probes enlisted in C. C. RNA probes with the canonical UUUUU HuR binding site located either next to A (0A) or m6A (0m6A) or separated by a 12-nucleotide spacer (12A and 12m6A). D. HuR RIP-qPCR of Pou5f1, Igfbp3, and Otx2 from kd versus control cells. E. RT-qPCR of Pou5f1, Igfbp3, and Otx2 in Actinomycin D-treated kd cells. In the case of Igfbp3, cells are also treated with and without siRNA targeting HuR. P values are generated using two-way ANOVA. F. RT-qPCR of HuR, Igfbp3, Otx2, and Pou5f1 in mESC with depleted HuR. shHuR#1-3: shRNAs against HuR. G. Argonaute 2 (Ago2) RIP–qPCR of Igfbp3 and Pou5f1 RNAs from kd versus control cells. H. Enrichment of genes showing increased RNA stability and expression among shared Mettl3 and Mettl14 targets. Targets are classified by whether they display Ago2 binding sites. I. Model: In wildtype mESCs, Mettl3 and Mettl14 methylate RNA synergistically and m6A methylation on some transcripts, particularly those encoding developmental regulators, blocks HuR binding, resulting in transcript destabilization. In Mettl3 and Mettl14 kd cells, loss of m6A allows HuR-mRNA interaction and attenuation of microRNA targeting, enhancing stability of transcripts especially those encoding developmental regulators, and promoting loss of the mESC ground state. A potentially methylated A is shown in red. Error bars from panels D-G represent means ± SEM from 3 separate experiments. One-tailed Student’s t-test, *P<0.05,**p<0.01,****P<0.0001 vs. scramble control. Scr: scramble.
Supplementary information
Supplementary Information
Supplementary Information (PDF 740 kb)
Supplementary Table 1
Supplementary Information (XLSX 1190 kb)
Supplementary Table 2
Supplementary Information (XLSX 3597 kb)
Supplementary Table 3
Supplementary Information (XLSX 33 kb)
Rights and permissions
About this article
Cite this article
Wang, Y., Li, Y., Toth, J. et al. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat Cell Biol 16, 191–198 (2014). https://doi.org/10.1038/ncb2902
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb2902
This article is cited by
-
Epigenetic modification of m6A regulator proteins in cancer
Molecular Cancer (2023)
-
Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers: biological functions and therapeutic applications
Biomarker Research (2023)
-
Transcriptome-wide profiling and quantification of N6-methyladenosine by enzyme-assisted adenosine deamination
Nature Biotechnology (2023)
-
Biological roles of adenine methylation in RNA
Nature Reviews Genetics (2023)
-
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Signal Transduction and Targeted Therapy (2023)